Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 20 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 28, 2025 | Tisotumab Vedotin | EMA EU | Malignant Cervical Neoplasm | Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease… | centralisedEMEA/H/C/005363 | approved | ema |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | Denosumab | EMA EU | cancer not stated in this record | Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 20, 2025 | Lazertinib | EMA EU | Lung Non-Small Cell Carcinoma | Lazcluze in combination with amivantamab is indicated for the first line treatment of adult patients with advanced non small cell lung… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Pomalidomide | EMA EU | Multiple Myeloma | Pomalidomide Teva in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 19, 2024 | Trastuzumab | EMA EU | cancer not stated in this record | Metastatic breast cancer (MBC) For the treatment of adult patients with HER2-positive MBC: as monotherapy for the treatment of those… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 22, 2024 | Nilotinib | EMA EU | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 26, 2024 | Pomalidomide | EMA EU | Multiple Myeloma | Pomalidomide Accord in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 27, 2024 | Eribulin | EMA EU | cancer not stated in this record | Eribulin Baxter is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 17, 2024 | Denosumab | EMA EU | cancer not stated in this record | Prevention of skeletal related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 19, 2024 | Retifanlimab | EMA EU | Merkel Cell Carcinoma | Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 16, 2024 | Pomalidomide | EMA EU | Multiple Myeloma | Pomalidomide Viatris in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 25, 2024 | Momelotinib | EMA EU | cancer not stated in this record | Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 7, 2023 | Elranatamab | EMA EU | Multiple Myeloma | Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 15, 2023 | Dabrafenib | EMA EU | High-Grade Glioma, NOS | Low-grade glioma Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2023 | Pirtobrutinib | EMA EU | cancer not stated in this record | Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 29, 2023 | Degarelix | EMA EU | Malignant Prostate Neoplasm | Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated: for treatment of adult male patients with advanced… |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| centralisedEMEA/H/C/006157 |
| approved |
| ema |
| Feb 14, 2025 | Denosumab | EMA EU | cancer not stated in this record | Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab… | centralisedEMEA/H/C/006156 | approved | ema |
| Feb 12, 2025 | Denosumab | EMA EU | cancer not stated in this record | Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with… | centralisedEMEA/H/C/006468 | approved | ema |
| Feb 12, 2025 | Denosumab | EMA EU | cancer not stated in this record | Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab… | centralisedEMEA/H/C/006424 | approved | ema |
| Feb 12, 2025 | Filgrastim | EMA EU | cancer not stated in this record | Zefylti is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with… | centralisedEMEA/H/C/006400 | approved | ema |
| Feb 12, 2025 | Belzutifan | EMA EU | cancer not stated in this record | Renal cell carcinoma (RCC) Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell… | centralisedEMEA/H/C/005636 | approved | ema |
| Feb 10, 2025 | Catumaxomab | EMA EU | cancer not stated in this record | Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule… | centralisedEMEA/H/C/005697 | approved | ema |
| Feb 3, 2025 | Serplulimab | EMA EU | cancer not stated in this record | Small cell lung cancer (SCLC) Hetronifly in combination with carboplatin and etoposide is indicated for the first‑line treatment of adult… | centralisedEMEA/H/C/006170 | approved | ema |
| centralisedEMEA/H/C/006074 |
| approved |
| ema |
| Jan 13, 2025 | Repotrectinib | EMA EU | Tumor-agnosticLung Non-Small Cell Carcinoma | Augtyro as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).… | centralisedEMEA/H/C/006005 | approved | ema |
| centralisedEMEA/H/C/006302 |
| approved |
| ema |
| Nov 14, 2024 | Mirvetuximab Soravtansine | EMA EU | Malignant Peritoneal Neoplasm | Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high… | centralisedEMEA/H/C/005036 | approved | ema |
| centralisedEMEA/H/C/006252 |
| approved |
| ema |
| Sep 19, 2024 | Rituximab | EMA EU | cancer not stated in this record | Treatment of Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and rheumatoid arthritis | centralisedEMEA/H/C/006224 | approved | ema |
| Sep 19, 2024 | Axitinib | EMA EU | Renal Cell Carcinoma | Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment… | centralisedEMEA/H/C/006206 | approved | ema |
| Sep 19, 2024 | Toripalimab | EMA EU | cancer not stated in this record | Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not… | centralisedEMEA/H/C/006120 | approved | ema |
| Sep 19, 2024 | Zolbetuximab | EMA EU | cancer not stated in this record | Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first line treatment of adult… | centralisedEMEA/H/C/005868 | approved | ema |
| centralisedEMEA/H/C/006315 |
| approved |
| ema |
| Aug 22, 2024 | Enzalutamide | EMA EU | Castration-Resistant Prostate Carcinoma | Enzalutamide Viatris is indicated:• as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with… | centralisedEMEA/H/C/006299 | approved | ema |
| Aug 22, 2024 | Odronextamab | EMA EU | cancer not stated in this record | Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two… | centralisedEMEA/H/C/006215 | approved | ema |
| Aug 22, 2024 | Erdafitinib | EMA EU | Urothelial Carcinoma | Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC),… | centralisedEMEA/H/C/006050 | approved | ema |
| centralisedEMEA/H/C/006273 |
| approved |
| ema |
| Jul 26, 2024 | Dasatinib | EMA EU | cancer not stated in this record | Dasatinib Accord Healthcare is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+)… | centralisedEMEA/H/C/006251 | approved | ema |
| Jul 26, 2024 | Bevacizumab | EMA EU | cancer not stated in this record | Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian,… | centralisedEMEA/H/C/005574 | approved | ema |
| Jul 24, 2024 | Pomalidomide | EMA EU | Multiple Myeloma | Pomalidomide Krka in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma… | centralisedEMEA/H/C/006314 | approved | ema |
| Jul 24, 2024 | Pomalidomide | EMA EU | Multiple Myeloma | Treatment of adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Pomalidomide… | centralisedEMEA/H/C/006294 | approved | ema |
| Jul 24, 2024 | Sugemalimab | EMA EU | Lung Non-Small Cell Carcinoma | Cejemly in combination with platinum-based chemotherapy is indicated for the first line treatment of adults with metastatic non small cell… | centralisedEMEA/H/C/006088 | approved | ema |
| Jul 24, 2024 | Paclitaxel | EMA EU | cancer not stated in this record | Apexelsin monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for… | centralisedEMEA/H/C/005997 | approved | ema |
| centralisedEMEA/H/C/006191 |
| approved |
| ema |
| Jun 20, 2024 | Fruquintinib | EMA EU | Malignant Colorectal Neoplasm | Fruzaqla as monotherapy is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously… | centralisedEMEA/H/C/005979 | approved | ema |
| Jun 17, 2024 | Capivasertib | EMA EU | Malignant Breast Neoplasm | Truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive,… | centralisedEMEA/H/C/006017 | approved | ema |
| centralisedEMEA/H/C/006378 |
| approved |
| ema |
| May 16, 2024 | Denosumab | EMA EU | cancer not stated in this record | Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab… | centralisedEMEA/H/C/005964 | approved | ema |
| centralisedEMEA/H/C/006194 |
| approved |
| ema |
| Apr 19, 2024 | Nintedanib | EMA EU | cancer not stated in this record | Nintedanib Accord is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Accord is also indicated… | centralisedEMEA/H/C/006179 | approved | ema |
| Apr 19, 2024 | Tislelizumab | EMA EU | cancer not stated in this record | Non-small cell lung cancer (NSCLC)Tizveni in combination with pemetrexed and platinum-containing chemotherapy is indicated for the… | centralisedEMEA/H/C/005542 | withdrawn | ema |
| centralisedEMEA/H/C/006195 |
| approved |
| ema |
| Feb 9, 2024 | Eribulin | EMA EU | cancer not stated in this record | Mevlyq is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at… | centralisedEMEA/H/C/006134 | approved | ema |
| centralisedEMEA/H/C/005768 |
| approved |
| ema |
| Jan 5, 2024 | Paclitaxel | EMA EU | cancer not stated in this record | Naveruclif monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment… | centralisedEMEA/H/C/006173 | approved | ema |
| Jan 5, 2024 | Azacitidine | EMA EU | cancer not stated in this record | Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation(HSCT)… | centralisedEMEA/H/C/006154 | approved | ema |
| Jan 5, 2024 | Adagrasib | EMA EU | Lung Non-Small Cell Carcinoma | Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C… | centralisedEMEA/H/C/006013 | approved | ema |
| Jan 5, 2024 | Trametinib | EMA EU | High-Grade Glioma, NOS | Low-grade glioma Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older… | centralisedEMEA/H/C/005886 | approved | ema |
| centralisedEMEA/H/C/005908 |
| approved |
| ema |
| centralisedEMEA/H/C/005885 |
| approved |
| ema |
| Nov 15, 2023 | Trastuzumab | EMA EU | cancer not stated in this record | Treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC). | centralisedEMEA/H/C/005769 | approved | ema |
| Nov 6, 2023 | Quizartinib | EMA EU | Acute Myeloid Leukemia | Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation… | centralisedEMEA/H/C/005910 | approved | ema |
| centralisedEMEA/H/C/005863 |
| approved |
| ema |
| centralisedEMEA/H/C/006048 |
| approved |
| ema |